



(51) International Patent Classification:

A61K 39/395 (2006.01) *A61P 25/28* (2006.01)
C07K 16/18 (2006.01) *A61K 39/00* (2006.01)

(21) International Application Number:

PCT/US2021/038591

(22) International Filing Date:

23 June 2021 (23.06.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/044,291 25 June 2020 (25.06.2020) US

(71) Applicant: **MERCK SHARP & DOHME CORP.**
[US/US]; 126 EAST LINCOLN AVENUE, RAHWAY,
New Jersey 07065-0907 (US).

(72) Inventors; and

(71) Applicants (*for US only*): **BAKER, Jeanne, E.** [US/US];
213 E. Grand Avenue, South San Francisco, California
94080 (US). **PARMENTIER BATTEUR, Sophie**
[US/US]; 241 Cheswold Lane, Haverford, Pennsylvania
19041 (US). **CHEN, Ming-Tang** [US/US]; 33 Avenue

Louis Pasteur, Boston, Massachusetts 02115-5727 (US).
CHENG, Alan, C. [US/US]; 213 E. Grand Avenue,
South San Francisco, California 94080 (US). **HSIEH,
Chung-Ming** [US/US]; 33 Avenue Louis Pasteur, Boston,
Massachusetts 02115-5727 (US). **MIECZKOWSKI, Carl**
[US/US]; 181 Copper Beech Glen, Hercules, California
94547 (US). **SUON, Sokreine** [US/US]; 770 Summeytown
Pike, West Point, Pennsylvania 19486 (US).

(74) Common Representative: **MERCK SHARP & DOHME
CORP.**; 126 EAST LINCOLN AVENUE, RAHWAY,
New Jersey 07065-0907 (US).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(54) Title: HIGH AFFINITY ANTIBODIES TARGETING TAU PHOSPHORYLATED AT SERINE 413




FIG. 4E

(57) Abstract: Provided herein are high affinity antibodies or antigen binding fragments thereof that specifically bind to human tau-pS413. Also provided are compositions, kits, methods, and uses involving such antibodies or antigen binding fragments thereof.

[Continued on next page]



(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*